| Literature DB >> 34514848 |
Kang Wang1, Dengchang Wu1, Caihong Ji1, Benyan Luo1, Chunjie Wang2, Zhongqin Chen1.
Abstract
Background: Patients with postacute anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis are often left with permanent memory impairments. Given that NMDA receptors are essential to memory encoding, and encoding processes have been suggested to contribute to the success of memory retrieval, we investigate whether postacute anti-NMDA receptor encephalitis leads to abnormal brain activation during verbal memory encoding and its potential effects on subsequent memory retrieval performance.Entities:
Keywords: anti-NMDA receptor encephalitis; brain activation; fMRI; hippocampus; verbal memory encoding
Mesh:
Substances:
Year: 2021 PMID: 34514848 PMCID: PMC9527060 DOI: 10.1089/brain.2021.0046
Source DB: PubMed Journal: Brain Connect ISSN: 2158-0014
Demographic and Clinical Data of the Patients
| Patient | IgG NMDA receptor antibodies (CSF titer) | Symptoms | Duration of unconsciousness, days | Treatment protocol | Hospital stay, months | Paraneoplastic syndrome | mRS score | AEDs at study time point | Time between initial discharge and data acquisition, months | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial | Total | Tumor | Resection | Before treatment | At study time point | |||||||
| 1 | 1:32 | Behavior, seizure | LOC, dyskinesia, seizure, behavior, cognition | 15–20 | High-dose steroids, IVIG, cyclophosphamide | 1.1 | None | / | 5 | 0 | Topiramate 50 mg/day | 6.5 |
| 2 | 1:32 | Behavior, dyskinesia | LOC, dyskinesia, seizure, behavior, cognition, autonomic instability | 20–25 | High-dose steroids, IVIG, cyclophosphamide | 1.2 | None | / | 5 | 1 | None | 9.3 |
| 3 | 1:32 | Seizure, LOC | LOC, dyskinesia, seizure, behavior, cognition, autonomic instability | 25–30 | IVIG, cyclophosphamide | 1.4 | None | / | 5 | 0 | None | 21 |
| 4 | 1:32 | Dyskinesia, seizure | Dyskinesia, seizure, behavior, cognition | NA | High-dose steroids, IVIG, rituximab | 1.2 | None | / | 4 | 1 | Oxcarbazepine 900 mg/day | 6.1 |
| 5 | 1:32 | Behavior | LOC, dyskinesia, seizure, behavior, cognition | 10–15 | High-dose steroids, IVIG, cyclophosphamide | 1.2 | None | / | 5 | 0 | None | 18.5 |
| 6 | 1:32 | Behavior, cognition | LOC, dyskinesia, seizures, behavior, cognition, autonomic instability | 700+ | High-dose steroids, plasmapheresis, IVIG, rituximab, cyclophosphamide | 26 | Mature cystic teratoma of left ovarian | Yes | 5 | 0 | None | 36.2 |
| 7 | 1:32 | Behavior | LOC, dyskinesia, seizures, behavior, cognition | 10–15 | High-dose steroids, IVIG, cyclophosphamide | 0.8 | None | / | 4 | 0 | None | 23.9 |
| 8 | 1:32 | Behavior, seizure | LOC, dyskinesia, seizures, behavior, cognition | 20–25 | High-dose steroids, IVIG, rituximab, cyclophosphamide | 1.2 | Mature cystic teratoma of bilateral ovarian | Yes | 5 | 0 | None | 8.3 |
| 9 | 1:3.2 | Behavior, dyskinesia | LOC, dyskinesia, seizures, behavior, cognition | 20–25 | High-dose steroids, IVIG, rituximab, cyclophosphamide | 1.3 | None | / | 5 | 2 | None | 13 |
| 10 | 1:3.2 | Behavior | LOC, behavior, cognition | 8–10 | High-dose steroids, IVIG | 0.7 | None | / | 4 | 0 | None | 6.5 |
| 11 | 1:10 | Seizure, behavior | LOC, dyskinesia, seizure, behavior, cognition | 15–20 | High-dose steroids, IVIG | 1.2 | None | / | 5 | 1 | None | 9.8 |
| 12 | 1:10 | Seizure, behavior, | LOC, seizure, behavior, cognition, autonomic instability | 20–25 | High-dose steroids, IVIG | 1.2 | None | / | 5 | 1 | None | 16 |
| 13 | 1:32 | Seizure, behavior | Seizure, behavior, cognition | NA | High-dose steroids, IVIG | 1.3 | Mature cystic teratoma of right ovarian | Yes | 5 | 0 | None | 23.2 |
| 14 | 1:32 | Behavior, seizure | LOC, seizure, behavior, cognition | 20–25 | High-dose steroids, IVIG | 1.3 | None | / | 4 | 0 | None | 21.5 |
| 15 | 1:10 | Seizure | LOC, seizure, behavior, cognition | 25–30 | High-dose steroids, IVIG, rituximab | 1.4 | None | / | 5 | 1 | None | 9.1 |
| 16 | 1:32 | Behavior | Dyskinesia, seizure, behavior, cognition | NA | High-dose steroids, IVIG, rituximab | 1.3 | None | / | 4 | 0 | None | 6.7 |
| 17 | 1:32 | Behavior, LOC | LOC, dyskinesia, seizure, behavior, cognition | 20–25 | High-dose steroids, IVIG, rituximab | 0.9 | None | 5 | 1 | None | 13.3 | |
| 18 | 1:10 | Seizure, behavior | LOC, seizure, behavior, cognition, autonomic instability | 25–30 | High-dose steroids, IVIG, rituximab | 1.4 | None | / | 5 | 1 | None | 9.2 |
| 19 | 1:10 | Behavior | Seizure, behavior, cognition | NA | High-dose steroids, IVIG, rituximab | 1.2 | None | / | 4 | 0 | None | 10.6 |
AEDs, antiepileptic drugs; CSF, cerebrospinal fluid; IVIG, intravenous immunoglobulin; LOC, loss of consciousness; mRS, modified Rankin Scale; NA, not applicable; NMDA, N-methyl-D-aspartate.
FIG. 1.Experimental design of the verbal memory task. (A) Event-related design for the fMRI. In each trial, subjects first heard a single sentence (encoding), followed by scanning. Then was followed by a number task (R0: 0 number; or R1: 5 numbers; or R2: 10 numbers), which was pseudorandomly displayed. This was followed by scanning and then followed by spoken free recall of the sentence (retrieval). (B) Three task conditions. fMRI, functional magnetic resonance imaging.
FIG. 2.Behavioral performance for both groups. The patients showed significant memory retrieval impairment than the controls. R0, 0 number. R1, 5 numbers. R2, 10 numbers. R0–R2, difference scores between R0 and R2. Error bar shows one standard error of the mean. **p < 0.01.
Summary of Significant Activation During the Memory Encoding Versus Number Baseline Comparison for Each Group
| Anatomical region | Hemisphere | MNI coordinates | Cluster size | Peak |
|---|---|---|---|---|
| Patients | ||||
| HG/PHG/FG | Left | (−36, −15, −27) | 111 | 6.87 |
| HG/PHG | Right | (27, −12, −18) | 71 | 6.65 |
| OFG/IFG | Left | (−39, 30, −15) | 48 | 7.15 |
| STG/MTG/ITG | Left | (−66, −15, 0) | 254 | 9.04 |
| STG/MTG/ITG | Right | (69, −12, 6) | 202 | 9.95 |
| Thalamus | Bilateral | (9, −12, 9) | 166 | 6.03 |
| mFPC | Left | (−9, 63, 9) | 40 | 6.19 |
| mPFC | Bilateral | (−6, 60, 33) | 62 | 6.99 |
| Controls | ||||
| STG/MTG | Left | (−48, −9, −6) | 91 | 4.97 |
| OFG/IFG | Left | (−51, 33, 3) | 54 | 4.72 |
| mPFC | Left | (−9, 51, 27) | 62 | 4.37 |
| Cerebellum | Right | (33, −75, −36) | 96 | 5.77 |
FG, fusiform gyrus; HG, hippocampus; ITG, inferior temporal gyrus; MNI, Montreal Neurological Institute; mPFC, medial prefrontal cortex; MTG, middle temporal gyrus; OFG/IFG, orbitofrontal/inferior frontal gyrus; PHG, parahippocampus; STG, superior temporal gyrus.
FIG. 3.Brain regions showed significant activation during the memory encoding versus number baseline comparison. (A) Activation in the patients and (B) activation in the healthy controls. All images were thresholded at voxel-wise p < 0.001 and a minimal cluster size of 30 voxels. The left side of each axial slice corresponds to the left hemisphere of the brain. FG, fusiform gyrus; HG, hippocampus; IFG, inferior frontal gyrus; ITG, inferior temporal gyrus; mPFC, medial prefrontal cortex; MTG, middle temporal gyrus; PHG, parahippocampus; STG, superior temporal gyrus. Color images are available online.
FIG. 4.Group differences in brain activation during the memory encoding versus number baseline contrast. Four clusters that are significant for the two-sample t test. Color images are available online.
Brain Regions Showed Greater Activation in the Patients than the Healthy Controls
| Anatomical region | Hemisphere | MNI coordinates | Cluster size | Peak |
|---|---|---|---|---|
| HG/PHG | Left | (−33, −15, −27) | 57 | 5.42 |
| HG/PHG | Right | (30, −12, −27) | 32 | 5.14 |
| STG | Right | (57, −18, −3) | 54 | 5.40 |
| Thalamus | Right | (9, −6, 3) | 34 | 4.73 |
FIG. 5.Brain–behavior correlations. (A) A negative correlation was found between activation of the left HG/PHG and overall content retrieval performance in the patients. (B–D) Similar correlations were found for the R0, R1, and R2 conditions. (E) A positive correlation was found between activation of the left HG/PHG and retrieval difference between the R0 and R2 conditions in the patients.